Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Investigational New Drugs|September 9, 2018
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemiaMuhammed H Rahaman, Yingyi Yu, Longjin Zhong, et al.European Journal of Medicinal Chemistry|February 13, 2021
Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agentsHao Shao, David W Foley, Shiliang Huang, et al.European Journal of Medicinal Chemistry|November 5, 2013
Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agentsHao Shao, Shenhua Shi, David W Foley, et al.International Journal of Pharmaceutics|September 17, 2016
Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptideWei Zhang, Sanjay Garg, Preethi Eldi, et al.Chemmedchem|March 29, 2014
Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluationSarah Diab, Theodosia Teo, Malika Kumarasiri, et al.British Journal of Pharmacology|August 12, 2017
Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agentsSolomon Tadesse, Laychiluh Bantie, Khamis Tomusange, et al.Molecular Oncology|August 10, 2019
Targeting CDK9 for treatment of colorectal cancerMuhammed H Rahaman, Frankie Lam, Longjin Zhong, et al.Oncotarget|October 4, 2014
Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73Frankie Lam, Abdullahi Y Abbas, Hao Shao, et al.Journal of Medicinal Chemistry|February 4, 2017
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and EvaluationSolomon Tadesse, Mingfeng Yu, Laychiluh B Mekonnen, et al.Journal of Medicinal Chemistry|January 11, 2013
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activitiesHao Shao, Shenhua Shi, Shiliang Huang, et al.Pageof 3